Vaxxitek HVT+IBD


live vaccine against infectious bursal disease and Marek's disease

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 09/04/2018

Authorisation details

Product details
Vaxxitek HVT+IBD
Agency product number
Active substance
live vHVT013-69 recombinant virus
International non-proprietary name (INN) or common name
live vaccine against infectious bursal disease and Marek's disease
  • Embryonated eggs
  • Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Date of issue of marketing authorisation valid throughout the European Union
Contact address
29 avenue Tony Garnier
69007 Lyon

Product information

15/02/2018 Vaxxitek HVT+IBD - EMEA/V/C/000065 - WS/1209/G


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

For active immunisation of chickens:

  • to prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.
    The onset of protection is from 2 weeks and the protection extends to 9 weeks;
  • to reduce mortality, clinical signs and lesions of Marek’s disease.
    The onset of protection is from 4 days. A single vaccination is sufficient to provide protection during the risk period.

Assessment history

How useful was this page?

Add your rating